Technology
Health
Pharmaceutical

Kindred Biosciences

$8.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (0.95%) Today
+$0.12 (1.41%) After Hours

Why Robinhood?

You can buy or sell KIN and other stocks, options, ETFs, and crypto commission-free!

About

Kindred Biosciences, Inc. Common Stock, also called Kindred Biosciences, is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. Read More The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Employees
146
Headquarters
Burlingame, California
Founded
2012
Market Cap
330.89M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
209.26K
High Today
$8.75
Low Today
$8.49
Open Price
$8.55
Volume
32.46K
52 Week High
$15.75
52 Week Low
$8.04

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Pets
2013 IPO
US
North America

News

Yahoo FinanceMay 10

Kindred Biosciences Q1 2019 Earnings Call Transcript

Image source: The Motley Fool. Kindred Biosciences (NASDAQ: KIN) Q1 2019 Earnings Call , 4:30 p.m. ET Operator Welcome to the first-quarter 2019 financial results conference call and webcast for Kindred Biosciences. [Operator instructions] Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in our forward-looking statements. For a description of important factors that could cause actual results to dif...

27
Yahoo FinanceMay 9

Kindred Biosciences Announces First Quarter 2019 Financial Results

SAN FRANCISCO, May 9, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs. For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share. Kindred Biosciences, Inc. Logo More "We are confident that Mirataz is on track to be a successful feli...

22
Yahoo FinanceMay 7

Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Kindred Biosciences, Inc. (NASDAQ:KIN) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Warren Buffett said that he likes 'a business with enduring competitive advantages that is run by able and owner-oriented people'. So it's nice to see ...

21

Earnings

-$0.46
-$0.40
-$0.35
-$0.29
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.